Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2019-11-15

FDA Approved: NOVOLIN 70/30 — Supplemental Application (Novo Nordisk)

View source ↗

Summary

FDA approved a supplemental application for NOVOLIN 70/30 (human insulin) submitted by Novo Nordisk; the snippet does not specify the exact labeling changes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NOVOLIN 70/30 (HUMAN INSULIN)

Snippet

SUPPL AP for NOVOLIN 70/30 (HUMAN INSULIN)